Technology | May 31, 2011

UPPI Offers UltraSPECT’s Nuclear Imaging Technology for Dose Reduction, Abbreviated Scan Times

May 31, 2011 — UltraSPECT, a provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces a multi-year distribution agreement with nuclear pharmacy network UPPI LLC for exclusive leasing and/or non-exclusive sale of UltraSPECT’s cardiac and bone imaging applications in the United States.

Ushering molecular imaging into a new age of precision and efficiency, UltraSPECT’s growing product line utilizes the company’s innovative wide-beam reconstruction (WBR) technology to enhance the performance of gamma cameras and PET scanners. The technology will cut either standard radiopharmaceutical dose requirements or imaging procedure time in half with no decrease in image quality, while enhancing image resolution. In some cases, exams can be performed in as little as a quarter of the standard procedure time. Additionally, advanced new UltraSPECT applications support a 50 percent reduction in both dose and procedure time.

UltraSPECT WBR’s lower dose requirements offer the benefit of minimizing radiation exposure for both patients and technologists, while abbreviated acquisition times reduce the possibility of patient motion artifacts and enhance patient throughput and comfort. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many WBR users the result is enhanced equipment utilization, revenues and patient satisfaction and referrals.

UltraSPECT’s WBR product line is compatible with most major manufacturers’ NM and PET systems as well as all clinical software packages. The technology is a far more cost effective dose reduction alternative to today’s new low-dose SPECT cameras with multiple focused detectors. WBR’s half-dose, half-time and quarter-time capabilities are already successfully utilized in hundreds locations throughout the United States and Europe.

For more information: www.UPPI.org, www.ultraspect.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init